Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Nuvectis Pharma (NVCT) Interest & Investment Income (2022 - 2026)

Nuvectis Pharma has reported Interest & Investment Income over the past 5 years, most recently at $210000.0 for Q1 2026.

  • Quarterly results put Interest & Investment Income at $210000.0 for Q1 2026, down 11.02% from a year ago — trailing twelve months through Mar 2026 was $1.1 million (up 28.9% YoY), and the annual figure for FY2025 was $1.1 million, up 33.65%.
  • Interest & Investment Income reached $210000.0 in Q1 2026 per NVCT's latest filing, down from $303000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $332000.0 in Q3 2025 and bottomed at $2000.0 in Q1 2022.
  • Median Interest & Investment Income over the past 5 years was $210000.0 (2026), compared with a mean of $175000.0.
  • The largest annual shift saw Interest & Investment Income skyrocketed 2500.0% in 2023 before it dropped 25.63% in 2024.
  • Over 5 years, Interest & Investment Income stood at $82000.0 in 2022, then soared by 197.56% to $244000.0 in 2023, then decreased by 17.62% to $201000.0 in 2024, then surged by 50.75% to $303000.0 in 2025, then crashed by 30.69% to $210000.0 in 2026.
  • Business Quant data shows Interest & Investment Income for NVCT at $210000.0 in Q1 2026, $303000.0 in Q4 2025, and $332000.0 in Q3 2025.